Funding for this research was provided by:
Received: 4 November 2020
Accepted: 10 November 2020
First Online: 19 November 2020
Ethics approval and consent to participate
: This study was approved by an independent Medical Ethics Committee attached to the University Hospital of Ghent and the University of Ghent (reference BC-07652) on May 22<sup>nd</sup> 2020, after consultation of the ethics committees of each Belgian centre where this study will be carried out. Eligible subjects may only be included in the study after providing written Ethics Committee-approved informed consent, or, if incapable of doing so, after such consent has been provided by a legally acceptable representative(s) of the subject, after receiving full explanation, having received sufficient time to consider the trial, asking questions and receiving satisfying responses to all questions.
: Not applicable.
: JD, CB, KVD, EDL, BM, AV, AD, BD, SV, MV, TD, MV, TG, EVB, CVDS and BNL declare that they have no competing interests. ML, TS, LD, RB and JS are full time employees of UCB Pharma.